HUTCHMED Reports $457M Profit, $286M Oncology Revenue and 26% FRUZAQLA Growth
HUTCHMED reported 2025 consolidated profit of $457 million, driven by a $416 million equity gain, oncology revenue of $286 million (including $71 million in upfronts) and $1.4 billion cash. FRUZAQLA sales rose 26% to $366 million overseas, China H2 sales rebounded 21%, with 2026 oncology revenue guidance of $330–450 million.
1. Consolidated Financial Results
HUTCHMED reported 2025 consolidated profit of $457 million, propelled by a $416 million gain from an SPL equity divestment. Oncology business revenue reached $286 million, including $71 million from R&D-related upfront payments, milestones and service income, supported by $1.4 billion in cash reserves.
2. FRUZAQLA Global and China Performance
FRUZAQLA achieved $366 million in overseas sales, a 26% year-over-year increase, with launches in over 38 countries. In China, domestic oncology sales rebounded 21% in the second half, driven by expanded reimbursement for endometrial cancer and productivity initiatives.
3. R&D Strategy and ATTC Platform
R&D spending declined to $148 million in 2025 as late-stage registration trials progressed, with focus shifting toward the ATTC platform. Management indicated potential R&D investment growth toward $200–300 million as ATTC programs 251, 580 and 830 advance in global clinical development.
4. 2026 Outlook and Guidance
For 2026, oncology business revenue guidance was set at $330–450 million, underpinned by stronger domestic product growth, continued FRUZAQLA expansion and potential ATTC partnerships. The company’s $1.4 billion cash position offers capacity for in-licensing and M&A opportunities.